Buruli-RifDACC: Evaluation of the efficacy and cost-effectiveness of high-dose versus standard-dose rifampicin on outcomes in Mycobacterium ulcerans disease, a protocol for a randomised controlled trial in Ghana
2022NIHR Open ResearchJournalOpen access
10.3310/nihropenres.13332.1Full text3 citations